by John Conrad | Dec 3, 2024 | Member News
COUR Pharmaceuticals has secured a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize its tolerogenic nanoparticle treatments for autoimmune conditions. The partnership, announced via press release...
by John Conrad | Dec 2, 2024 | iBIO News
The newly released TECONOMY/BIO report, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions,” paints an impressive picture of Illinois’ life sciences industry. The data reveals an industry that’s not just...
by John Conrad | Dec 2, 2024 | iBIO News
The pharmaceutical industry faces a pivotal moment as political shifts introduce new dimensions of uncertainty into our operating environment. The recent election outcomes and potential leadership changes at key health agencies are reshaping the landscape for...
by John Conrad | Nov 14, 2024 | iBIO News
In a significant move to enhance science education across Illinois, the Illinois Biotechnology Innovation Organization (iBIO) has launched its innovative “LabShare” program. This groundbreaking program connects surplus laboratory equipment from iBIO member...
by John Conrad | Nov 13, 2024 | iBIO News
This month’s G2G report features 148 funding opportunities totaling over $500 million in non-dilutive funding for life sciences companies. Through iBIO’s G2G Consulting partnership, members have exclusive access to these comprehensive resources that help...
